Gland Pharma Limited (BOM:543245)

Gland Pharma Statistics

Total Valuation

Gland Pharma has a market cap or net worth of INR 288.59 billion. The enterprise value is 259.59 billion.

Market Cap	288.59B
Enterprise Value	259.59B

Important Dates

The next estimated earnings date is Wednesday, January 28, 2026.

Earnings Date	Jan 28, 2026
Ex-Dividend Date	Aug 14, 2025

Share Statistics

Current Share Class	164.76M
Shares Outstanding	n/a
Shares Change (YoY)	-0.01%
Shares Change (QoQ)	-0.00%
Owned by Insiders (%)	0.01%
Owned by Institutions (%)	37.49%
Float	73.18M

Valuation Ratios

The trailing PE ratio is 36.51 and the forward PE ratio is 26.78.

PE Ratio	36.51
Forward PE	26.78
PS Ratio	4.97
PB Ratio	3.02
P/TBV Ratio	3.15
P/FCF Ratio	65.15
P/OCF Ratio	33.39
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.95, with an EV/FCF ratio of 58.60.

EV / Earnings	32.84
EV / Sales	4.47
EV / EBITDA	18.95
EV / EBIT	26.74
EV / FCF	58.60

Financial Position

The company has a current ratio of 4.13, with a Debt / Equity ratio of 0.03.

Current Ratio	4.13
Quick Ratio	2.79
Debt / Equity	0.03
Debt / EBITDA	0.22
Debt / FCF	0.68
Interest Coverage	21.58

Financial Efficiency

Return on equity (ROE) is 8.61% and return on invested capital (ROIC) is 6.39%.

Return on Equity (ROE)	8.61%
Return on Assets (ROA)	5.35%
Return on Invested Capital (ROIC)	6.39%
Return on Capital Employed (ROCE)	9.62%
Revenue Per Employee	13.33M
Profits Per Employee	1.82M
Employee Count	4,351
Asset Turnover	0.51
Inventory Turnover	1.42

Taxes

In the past 12 months, Gland Pharma has paid 3.94 billion in taxes.

Income Tax	3.94B
Effective Tax Rate	33.26%

Stock Price Statistics

The stock price has decreased by -3.86% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-3.86%
50-Day Moving Average	1,879.98
200-Day Moving Average	1,752.77
Relative Strength Index (RSI)	38.26
Average Volume (20 Days)	3,918

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Gland Pharma had revenue of INR 58.01 billion and earned 7.90 billion in profits. Earnings per share was 47.98.

Revenue	58.01B
Gross Profit	34.00B
Operating Income	9.71B
Pretax Income	11.84B
Net Income	7.90B
EBITDA	13.52B
EBIT	9.71B
Earnings Per Share (EPS)	47.98

Balance Sheet

The company has 32.02 billion in cash and 3.02 billion in debt, giving a net cash position of 29.00 billion.

Cash & Cash Equivalents	32.02B
Total Debt	3.02B
Net Cash	29.00B
Net Cash Per Share	n/a
Equity (Book Value)	95.63B
Book Value Per Share	580.47
Working Capital	53.39B

Cash Flow

In the last 12 months, operating cash flow was 8.64 billion and capital expenditures -4.21 billion, giving a free cash flow of 4.43 billion.

Operating Cash Flow	8.64B
Capital Expenditures	-4.21B
Free Cash Flow	4.43B
FCF Per Share	n/a

Margins

Gross margin is 58.61%, with operating and profit margins of 16.73% and 13.62%.

Gross Margin	58.61%
Operating Margin	16.73%
Pretax Margin	20.41%
Profit Margin	13.62%
EBITDA Margin	23.30%
EBIT Margin	16.73%
FCF Margin	7.64%

Dividends & Yields

This stock pays an annual dividend of 18.00, which amounts to a dividend yield of 1.04%.

Dividend Per Share	18.00
Dividend Yield	1.04%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	1
Payout Ratio	37.52%
Buyback Yield	0.01%
Shareholder Yield	1.05%
Earnings Yield	2.74%
FCF Yield	1.53%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	6